Picking up post #4: that is the part I would want checked first. A methods point on Warfarin and altered intake rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
Posting this under the heading it deserves: Warfarin and altered intake: the monitoring argument — the long version Everything below is what sits behind that.
A narrow question about Warfarin and altered intake, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
I had written a reply contradicting the opening post and deleted it. Here is what survived.
Agreed on Warfarin and altered intake, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
Adding the measurement that the opening post says would settle it.
Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose adjustment of the secretagogue and close monitoring. The combination is not contraindicated but requires active management.
Marking my uncertainty on Warfarin and altered intake explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
I have no financial interest in anything named in this thread and I want to say so before I comment on Warfarin and altered intake, because it is the sort of subject where it matters.
On post #6 — agreed on the reasoning, with one qualification.
Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.
That is a description of practice, not a recommendation of it.
One caution on Warfarin and altered intake: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Thank you for taking the time. That was more work than a reply usually is.
Post #9 and I disagree about the size of the effect, not about the direction.
The most defensible general position in this subcategory: identify the plausible mechanism, check whether it has been studied, and where it has not, say that rather than filling the gap.
Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you are on it; monitoring INR more frequently during weight loss is reasonable.
Post #13 put the caveat in the right place and I want to underline it.
A pharmacist can answer most questions in this subcategory in a few minutes with access to a proper interaction database, and that access is the thing a forum does not have.
Speaking for myself and not for anyone else who has posted here.
Grateful for the specificity. Vague answers to this question are what sent me looking.
Warfarin and altered intake: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Right, and stated more narrowly than I would have dared to state it.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
Worth separating two things that post #20 runs together.
I would keep Warfarin and altered intake and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.
I would not lead a decision with this, but I would not ignore it either.
Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.
Everything in post #29 holds. The case it does not cover is the one I have.
Warfarin and altered intake is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.